Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. Invex has focussed on reformulating Exenatide to deliver it in a way that enables exploitation of its previously unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. This once per week injectable formulation is known as Presendin™, which is manufactured under a clinical and commercial supply agreement signed in September 2021 by Peptron Inc. (Daejeon, South Korea). By exploiting the safety record of Exenatide and successfully solving the required reformulation challenges, Invex has already progressed to a registration-directed Phase III clinical trial in IIH to obtain the necessary market approvals for Presendin™ in Europe, the UK and Australia. Thereafter, the Company will seek US registration following further discussions with the US FDA, which may require an additional clinical trial. In addition, Invex has additional plans to conduct clinical trials of Exenatide to treat other pressure-related neurological conditions.